EGFR-tyrosine kinase inhibitors (EGFR-TKIs), such as gefitinib [7, 8], erlotinib [9], and afatinib [10], display significant efficacy against EGFR-mutated NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.